Reslizumab

Reslizumab

Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.

 

 

[accordions]
[accordion title= “Biological Description“]

Description Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
Targets&IC50 IL-5-dependent cell proliferation:91.1pM

[/accordion]

 

 

 

[accordions]
[accordion title= “References and Literature“]

1. Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298.2. Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4.

[/accordion]